Analyse Septerna, Inc. (SEPN) — Kairos Score 63/100

À propos de Septerna, Inc.

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 0 achats et 1 ventes déclarés par les dirigeants de Septerna, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur SEPN dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur SEPN.

• Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?
• Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.